日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab

对接受阿特珠单抗治疗的晚期非小细胞肺癌患者外周血 T 细胞谱和血浆蛋白质组学进行分析

Mouri, Atsuto; Kagamu, Hiroshi; Tamada, Koji; Nishio, Makoto; Akamatsu, Hiroaki; Goto, Yasushi; Hayashi, Hidetoshi; Miura, Satoru; Gemma, Akihiko; Yoshino, Ichiro; Misumi, Toshihiro; Saito, Ryota; Yanagitani, Noriko; Masaki, Fujita; Nokihara, Hiroshi; Nishino, Kazumi; Seike, Masahiro; Hase, Tetsunari; Hataji, Osamu; Takeoka, Hiroaki; Kawashima, Yosuke; Kuroki, Hirotaka; Sugimoto, Masamichi; Kuriki, Hiroshi; Mitsudomi, Tetsuya

Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors

利用溴结构域和末端结构域抑制剂克服奥希替尼耐药性的新方法

Miyashita, Yosuke; Tajima, Ken; Izumi, Kenta; Matsumoto, Naohisa; Hayakawa, Daisuke; Nakamura, Ikuko Takeda; Katayama, Isana; Wibowo, Adityo; Matsuda, Hironari; Winardi, Wira; Amien, Bagus Radityo; Mitsuishi, Yoichiro; Takahashi, Fumiyuki; Nakamura, Kohta; Uchibori, Ken; Yanagitani, Noriko; Hayashi, Takuo; Takamochi, Kazuya; Suzuki, Kenji; Katayama, Ryohei; Takahashi, Kazuhisa

A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC

FLAURA2 研究结果的简明摘要:奥希替尼一线治疗(联合或不联合化疗)在未经治疗的 EGFR 突变晚期非小细胞肺癌患者中的疗效

Planchard, David; Jänne, Pasi A; Cheng, Ying; Yang, James Chih-Hsin; Yanagitani, Noriko; Kim, Sang-We; Sugawara, Shunichi; Yu, Yan; Fan, Yun; Geater, Sarayut Lucien; Laktionov, Konstantin; Lee, Chee Khoon; Valdiviezo, Natalia; Ahmed, Samreen; Maurel, Jean-Marc; Andrasina, Igor; Goldman, Jonathan; Ghiorghiu, Dana; Rukazenkov, Yuri; Todd, Alex; Kobayashi, Kunihiko

Significance of Platinum-Based Chemotherapy With Programmed Death-1 Blockade in Limited Disease Small Cell Lung Cancer: A Retrospective Study

铂类化疗联合程序性死亡受体1(PD-1)阻断治疗局限期小细胞肺癌的意义:一项回顾性研究

Shiono, Ayako; Imai, Hisao; Kaira, Kyoichi; Abe, Takanori; Sato, Yuki; Yamamoto, Ken; Watanabe, Hiroki; Tsuchiya-Kawano, Yuko; Tamiya, Akihiro; Osaki, Takashi; Yanagitani, Noriko; Tanzawa, Shigeru; Sumi, Toshiyuki; Yoshimine, Kohei; Matsui, Yohei; Endo, Satoshi; Shibata, Kazuhiko; Takemoto, Shinnosuke; Miura, Yosuke; Nagai, Yoshiaki; Nakagawa, Junichi; Tsuda, Takeshi; Kagamu, Hiroshi

Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial

阿特珠单抗联合铂类药物加培美曲塞,加或不加贝伐珠单抗治疗转移性非鳞状非小细胞肺癌:一项3期随机临床试验

Shiraishi, Yoshimasa; Kishimoto, Junji; Sugawara, Shunichi; Mizutani, Hideaki; Daga, Haruko; Azuma, Koichi; Matsumoto, Hirotaka; Hataji, Osamu; Nishino, Kazumi; Mori, Masahide; Shukuya, Takehito; Saito, Haruhiro; Tachihara, Motoko; Hayashi, Hidetoshi; Tsuya, Asuka; Wakuda, Kazushige; Yanagitani, Noriko; Sakamoto, Tomohiro; Miura, Satoru; Hata, Akito; Okada, Morihito; Kozuki, Toshiyuki; Sato, Yuki; Harada, Taishi; Takayama, Koichi; Yamamoto, Nobuyuki; Nakagawa, Kazuhiko; Okamoto, Isamu

Serum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors

血清 CYFRA 21-1 作为接受免疫检查点抑制剂治疗的非小细胞肺癌患者的预后标志物

Miyadera, Keiki; Kakuto, Sho; Sugai, Mayu; Tsugitomi, Ryosuke; Amino, Yoshiaki; Uchibori, Ken; Yanagitani, Noriko; Sugiura, Hisatoshi; Seike, Masahiro; Nishio, Makoto; Ariyasu, Ryo

Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051

预防性使用培非格司亭可降低晚期非小细胞肺癌化疗免疫治疗后接受雷莫芦单抗联合多西他赛治疗患者的发热性中性粒细胞减少症:NEJ051 研究的事后分析

Miura, Keita; Yamaguchi, Ou; Mori, Keita; Nakamura, Atsushi; Tamiya, Motohiro; Oba, Tomohiro; Yanagitani, Noriko; Mizutani, Hideaki; Ninomiya, Takashi; Kajiwara, Tomosue; Ito, Kentaro; Miyanaga, Akihiko; Arai, Daisuke; Kodama, Hiroaki; Kobayashi, Kunihiko; Kaira, Kyoichi

KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancer

KEYNOTE-434 B 部分:一项评估 epacadostat、pembrolizumab 和化疗联合治疗既往未接受治疗的日本晚期非小细胞肺癌患者的 1 期研究

Yamamoto, Noboru; Satouchi, Miyako; Doi, Toshihiko; Fujiwara, Yutaka; Yanagitani, Noriko; Kawa, Yoshitaka; Yoh, Kiyotaka; Leopold, Lance; Munteanu, Mihaela; Sawada, Takashi; Han, Shirong; Noguchi, Kazuo; Nishio, Makoto

Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion

奥希替尼治疗伴有恶性胸腔积液的EGFR突变阳性非小细胞肺癌患者的疗效

Kiritani, Ayu; Amino, Yoshiaki; Uchibori, Ken; Akita, Takahiro; Harutani, Yuhei; Ogusu, Shinsuke; Tsugitomi, Ryosuke; Manabe, Ryo; Ariyasu, Ryo; Kitazono, Satoru; Yanagitani, Noriko; Nishio, Makoto

Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers

利用肿瘤标志物鉴别ALK融合基因阳性和EGFR突变阳性肺癌

Akita, Takahiro; Ariyasu, Ryo; Kakuto, Sho; Miyadera, Keiki; Kiritani, Ayu; Tsugitomi, Ryosuke; Amino, Yoshiaki; Uchibori, Ken; Kitazono, Satoru; Yanagitani, Noriko; Tasaka, Sadatomo; Nishio, Makoto